Challenges of microarray data and the evaluation of gene expression profile signatures

Cancer Investigation

Volumn 26, Issue 4, 2008, Pages 327-332

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR; MESSENGER RNA; TAMOXIFEN; TRASTUZUMAB;

ACCURACY; BIOCHIP; BIOTECHNOLOGY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CHROMOSOME ANALYSIS; CLASSIFICATION; CLUSTER ANALYSIS; COMPARATIVE STUDY; DIFFERENTIAL DISPLAY; DNA DETERMINATION; DNA HYBRIDIZATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HIGH RISK PATIENT; HUMAN; MICROARRAY ANALYSIS; OLIGONUCLEOTIDE PROBE; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE;

DNA, COMPLEMENTARY; DNA, NEOPLASM; FALSE POSITIVE REACTIONS; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RNA, MESSENGER; RNA, NEOPLASM; VALIDATION STUDIES AS TOPIC;

EID: 42649109697     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801971032     Document Type: Review

References (37)

1. Simon, R.M.; Korn, E.L.; McShane, L.M.; Radmacher, M.D.; Wright, G.W.; Zhao, Y. Design and Analysis of DNA Microarray Investigations. New York: Springer, 2003.
2. Korn, E.L.; McShane, L.M.; Troendle, I.F.; Rosenwald, A.; Simon, R. Identifying pre-post chemotherapy differences in gene expression in breast tumors: a statistical method appropriate for this aim. Br J Cancer 2002; 86, 1093-1096.
3. Yang, S.X.; Simon, R.M.; Tan, A.R.; Nguyen, D.; Swain, S.M. Gene expression patterns and profile changes pre- and post-Erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 2005, 11, 6226-6232.
4. Sotiriou, C.; Neo, S.Y.; McShane, L.M.; et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA 2003, 100(18), 10393-10398.
5. Desai, K.V.; Xiao, N.; Wang, W.; et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002, 99, 6967-6972.
6. Simon, R. Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. Br J Cancer 2003, 89, 1599-1604.
7. Simon, R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005, 97, 866-867.
8. van't Veer, L,J.; Dai, H.; Vijver MJvd.; et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
9. Vijver, M.J.v.D.; He, Y.D.; Veer, L.J.v.t.; et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 2002, 347(25), 1999-2009.
10. Ma, X.J.; Wang, Z.; Ryan, P.D.; et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5, 1-10.
11. Ayers, M.; Symmans, W.F.; Stec, J.; et al. Gene expression profiles predict complete patholo gic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2005, 22(12), 2284-2293.
12. Jansen, M.P.H.M.; Foekens, J.A.; Staveren, I.L.v.; et al. Molecular classification of Tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23(4), 732-740.
13. Perou, C.M.; Sorlie, T.; Eisen, M.B.; et al. Molecular portraits of human breast tumors. Nature 2000, 406, 747-752.
14. Simon, R.; Radmacher, M.D.; Dobbin, K.; McShane, L.M. Pitfalls in the analysis of DNA microarray data: class prediction methods. J Natl Cancer Inst 2003, 95, 14-18.
15. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc Ser B 1995, 57, 289-300.
16. Tusher, V.G.; Tibshirani, R.; Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci 2001, 98, 5116-5121.
17. Simon, R.; Lam, A.P. BRB-ArrayTools Users Guide (Version 34). Bethesda, MD: Biometric Research Branch National Cancer Institute, 2005. Technical Report 46, hhtp://linus.nci. nih.gov./brb.
18. Subramanian, A.; Tamayo, P.; Mootha, V.K. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102 (43), 15545-15550.
19. Tian, L.; Greenberg, S.A.; Kong, S.W.; Altschuler, J.; Kohane, I.S.; Park, P.J. Discovering statisti cally significant pathways in expression profiling studies. Proc Natl Acad Sci USA 2005, 102 (38), 13544-13549.
20. Radmacher, M.D.; McShane, L.M.; Simon, R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002, 9, 505-511.
21. Dudoit, S.; Fridlyand, J. Classification in microarray experiments. In: Speed T, ed. Statisti cal Analysis of Gene Expression Microarray Data. New York: Chapman & Hall/CRC, 2003, 93-158.
22. Rosenwald, A.; Wright, G.; Chan, W.C.; et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med 2002, 346, 1937-1947.
23. Michiels, S.; Koscielny, S.; Hill, C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005, 365, 488-492.
24. Molinaro, A.M.; Simon, R.; Pfeiffer, R.M. Prediction error estimation: a comparison of resampling methods. Bioinformatics 2005, 21 (15), 3301-3307.
25. Simon, R. When is a genomic classifier ready for prime time? Nat Clin Pract Oncol 2004, 1 (1), 2-3.
26. Simon, R. A roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005, 23, 7332-7341.
27. Dobbin, K.; Beer, D.G.; Meyerson, M.; et al. Inter-laboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 2005, 11, 565-572.
28. Paik, S.; Shak, S.; Tang, G.; et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004, 351, 2817-2826.
29. Simon, R.; Altaian, D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994, 69, 979-985.
30. Bast, R.C.; Ravdin, P.; Hayes, D.P.; et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19, 1865-1878.
31. Simon, R.; Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004, 10, 6759-6763, supplement and correction 2006, 12, 3229.
32. Maitournam, A.; Simon, R. On the efficiency of targeted clinical trials. Stat Med 2005, 24, 329-339.
33. Simon, R.; Wang, S.J. Use of genomic signatures in therapeutics development. Pharmacogenomics J 2006, 6, 166-173.
34. Freidlin, B.; Simon, R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005, 11, 7872-7878.
35. Simon, R. Guidelines for the design of clinical studies for development and validation of therapeutically relevant biomarkers and biomarker based classification systems. In: Hayes DP, Gasparini G, eds. Biomarkers in Breast Cancer: Molecular Diagnostics for Predictingand Monitoring Therapeutic Effect. New York: Humana Press, 2005, 3-16.
36. Sargent, D.J.; Conley, B.A.; Allegra, C.; Collette, L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005, 23 (9), 2020-2027.
37. Pusztai, L.; Hess, K.R. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol 2004, 15, 1731-1737.